Pete Stavropoulos

Stock Analyst at Cantor Fitzgerald

(1.79)
# 3,230
Out of 4,918 analysts
50
Total ratings
27.08%
Success rate
-3.49%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Pete Stavropoulos

Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.89
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $33.63
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107$100
Current: $20.96
Upside: +377.10%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.95
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $12.29
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.58
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.21
Upside: -
Alector
Nov 26, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.45
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.46
Upside: -
Verastem
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.11
Upside: -
Initiates: Overweight
Price Target: n/a
Current: $20.70
Upside: -
Reiterates: Overweight
Price Target: $5
Current: $5.89
Upside: -15.04%
Reiterates: Overweight
Price Target: $13
Current: $1.36
Upside: +859.41%
Reiterates: Overweight
Price Target: $8
Current: $10.60
Upside: -24.53%